RNS60 was well tolerated when inhaled twice daily at home as part of an expanded access program (EAP) for people with ...

AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).

Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell ...

Columnist Dagmar Munn explains how the use of a shoehorn not only helps her put on shoes, but also allows for some gentle ...

RAG-17 therapy slowed functional decline and stabilized or improved breathing in people with ALS who carry mutations in the SOD1 gene.